Advance In Triple-negative Breast Cancer

Objective : Discuss the latest research progress of three negative breast cancerMethods:The latest domestic and foreign literature was summarized and analysised comprehensivelyResults : Triple-negative breast cancer(TNBC) is defined by the lack of immunohistochemical expression of the estrogen and progesterone receptors and human epidermal growth factor receptor 2(EGFR2). Most TNBC has a basal-like molecular phenotype by gene expression profiling and shares clinical and pathological features with hereditary BRCA1 related breast cancers. TNBC subgroups respond differentially to specific targeted agents. We evaluates the activity of available chemotherapy and targeted agents in TNBC. A systematic review of Pub Med and conference databases was carried out to identify randomised clinical trials reporting outcomes in women with TNBC treated with chemotherapy and targeted agents. TNBC being a chemosensitive entity, combination with targeted agents have not produced substantial improvements in outcomes,reasonably select patients, combined with targeted drugs rationally, to make the curative effect of success.Conclusion:As a special type of breast cancer, the pathogenesis of TNBC is unknown at present. Clinical data showed that the risk factors, such as race, age, menopausal status, the use of hormonal contracepties, histological grade is high, and was positively related with TNBC associated with advanced disease independent. There is no specific first-line therapy, the researchers focused on from different aspects, such as the genetic level,receptors, such as immune regulation, signaling pathways were studied. Due to the low incidence of the disease, at present there are only a few clinical trials. Therefore, we are looking forward to a larger clinical trials, in the future..